1188-21-2

  • Product NameN-Acetyl-L-Leucine
  • Molecular FormulaC8H15NO3
  • Molecular Weight173.212
  • Purity99%
  • Appearancewhite crystalline powder
Inquiry

Product Details

Quick Details

  • CasNo: 1188-21-2
  • Molecular Formula: C8H15NO3
  • Appearance: white crystalline powder
  • Purity: 99%

High Purity N-Acetyl-L-Leucine 1188-21-2 In Medicine

  • Molecular Formula:C8H15NO3
  • Molecular Weight:173.212
  • Appearance/Colour:white crystalline powder 
  • Vapor Pressure:1.77E-06mmHg at 25°C 
  • Melting Point:187-190 °C(lit.) 
  • Refractive Index:-22 ° (C=5, EtOH) 
  • Boiling Point:369.7 °C at 760mmHg 
  • PKA:3.67±0.10(Predicted) 
  • Flash Point:177.4 °C 
  • PSA:66.40000 
  • Density:1.069 g/cm3 
  • LogP:1.01270 

N-Acetyl-L-leucine(Cas 1188-21-2) Usage

Chemical Properties

White crystalline powder

Uses

N-Acetyl-L-Leucine is an acetylated derivative of the essential amino acid leucine. It has a role as a metabolite. N-Acetyl-L-(-)-leucine (NALL) is used in the preparation of small molecule inhibitors of anti-apoptotic Bcl-2 family proteins. Also used in the preparation of amphiphilic copolymers involving hydrophobic amino acid and oligopeptide side chains for optical tumor imaging in vivo. NALL can be used as a symptomatic treatment for NPC.

Definition

ChEBI: The N-acetyl derivative of L-leucine.

European Community (EC) Number 214-706-3
NSC Number 758152
UNII E915HL7K2O
DSSTox Substance ID DTXSID6045870

InChI:InChI=1/C8H15NO3/c1-5(2)4-7(8(11)12)9-6(3)10/h5,7H,4H2,1-3H3,(H,9,10)(H,11,12)/p-1/t7-/m0/s1

1188-21-2 Relevant articles

Efficacy and safety of N-acetyl-l-leucine in Niemann–Pick disease type C

Tatiana Bremova-Ertl, Jens Claassen, Tomas Foltan, Jordi Gascon-Bayarri, Paul Gissen, Andreas Hahn, Anhar Hassan, Anita Hennig, Simon A. Jones, Miriam Kolnikova, Kyriakos Martakis, Jan Raethjen, Uma Ramaswami, Reena Sharma & Susanne A. Schneider

Journal of Neurology volume 269, pages1651–1662 (2022)

Objective To investigate the safety and efficacy of N-acetyl-l-leucine (NALL) on symptoms, functioning, and quality of life in pediatric (≥ 6 years) and adult Niemann–Pick disease type C …

Efficacy and Safety of N-Acetyl-L-Leucine in Children and Adults With GM2 Gangliosidoses

Kyriakos Martakis, Jens Claassen, Jordi Gascon-Bayari, Nicolina Goldschagg, Andreas Hahn, Anhar Hassan, Anita Hennig, Simon Jones, Richard Kay, Heather Lau, Susan Perlman, Reena Sharma, Susanne Schneider, Tatiana Bremova-Ertl

Neurology, 2023

This clinical trial investigated N-acetyl-l-leucine (NALL), an orally administered, modified amino acid in pediatric (≥6 years) and adult patients with GM2 gangliosidoses. …

1188-21-2 Process route

L-leucine
61-90-5,21675-61-6,25248-98-0,70-45-1

L-leucine

4-nitrophenol acetate
830-03-5

4-nitrophenol acetate

4-nitro-phenol
100-02-7,78813-13-5,89830-32-0

4-nitro-phenol

N-Ac-Leu
1188-21-2

N-Ac-Leu

Conditions
Conditions Yield
β‐cyclodextrin; In water; dimethyl sulfoxide; at 25 ℃; Rate constant; Mechanism; various conditions;
 
(S)-benzyl 2-acetamido-4-methylpentanoate
244250-56-4

(S)-benzyl 2-acetamido-4-methylpentanoate

N-Ac-Leu
1188-21-2

N-Ac-Leu

Conditions
Conditions Yield
With palladium 10% on activated carbon; hydrogen; In ethanol; at 50 ℃; for 3h;
81%
With palladium 10% on activated carbon; hydrogen; In ethanol; at 50 ℃; for 3h;
81%

1188-21-2 Upstream products

  • 463-51-4
    463-51-4

    Ketene

  • 61-90-5
    61-90-5

    L-leucine

  • 99-15-0
    99-15-0

    N-acetylleucine

  • 108-24-7
    108-24-7

    acetic anhydride

1188-21-2 Downstream products

  • 1492-11-1
    1492-11-1

    N-acetyl-L-leucine methyl ester

  • 67368-37-0
    67368-37-0

    N-acetyl-DL-leucine anilide

  • 26090-94-8
    26090-94-8

    N-acetyl-N'-methylleucinamide

  • 32483-15-1
    32483-15-1

    Ac-Leu-NHMe

;

Relevant Products